MedTrace Logo

Amplification and Selection of Antimicrobial Resistance in the Intestine II

NCT03140826 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-08-03

No results posted yet for this study

Summary

Stool samples will be collected from two groups of neutropenic patients in the case that a therapy with either meropenem or piperacillin/tazobactam is needed due to a suspected infection. The intestinal resistome will be determined and quantified using shotgun metagenomics. Based on this, regression models will be used to determine the actual selection pressure caused by these drugs, and both selective forces will be compared. The results will reveal if there is a drug that causes a lower selection pressure compared to the other. The study aims to generate knowledge that is required to design effective antibiotic stewardship programs.

Conditions

  • Antibiotic Selection Pressure

Interventions

DRUG

meropenem

Antibiotics to treat infections.

Sponsors & Collaborators

  • University Hospital of Cologne

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Matthias Willmann, Prof. Dr. · University Tuebingen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2020-07-31
Completion
2020-07-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03140826 on ClinicalTrials.gov